0.231

1.28% -0.003

Propanc Biopharma Inc (PPCB)

Overview News Price History Discussions Forecast

Propanc Biopharma Inc stock is traded at $0.231, with a volume of 1.32M. It is down -1.28% in the last 24 hours and down -49.02% over the past month. Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.

Previous Close:

$0.234

Open:

$0.217

24h Volume:

1.32M

Relative Volume:

1.18

Market Cap:

$3.49M

Revenue:

Net Income/Loss:

$-58.92M

P/E Ratio:

-0.00504

EPS:

-45.8429

Net Cash Flow:

$-401.10K

1W Performance:

+14.41%

1M Performance:

-49.02%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$0.2056

$0.231

1-Week Range:

$0.1629

$0.239

52-Week Range:

$0.1555

$9.36

Propanc Biopharma Inc Stock (PPCB) Company Profile

Name

Propanc Biopharma Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

61-03-9882-0780

Address

302/6 BUTLER STREET, CAMBERWELL, VICTORIA

Employee

Twitter

Next Earnings Date

Latest SEC Filings

PPCB's Discussions on Twitter

Compare PPCB vs MOBBW, SHMD, GOODO, PSNYW, DWLD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PPCB Propanc Biopharma Inc	2.87	244.39K	0	0	0	0.00
MOBBW Mobilicom Limited Warrants	2.22	3.25B	0	0	0	0.00
SHMD Schmid Group N V	8.69	536.01M	0	0	0	0.00
GOODO Gladstone Commercial Corporation	20.32	372.90M	0	0	0	0.00
PSNYW Polestar Automotive Holding Uk	2.8999	277.51M	2.07B	-1.42B	-1.37B	-0.6765
DWLD Davis Select Worldwide ETF	46.01	0	0	0	0	0.00

Propanc Biopharma Inc Stock (PPCB) Latest News

Feb 09, 2026

Certain Warrants of Propanc Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 10-FEB-2026. - marketscreener.com

Feb 09, 2026

Feb 05, 2026

Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market - The Manila Times

Feb 05, 2026

Lab tests: Propanc’s PRP slowed tumor growth 85%, human trial planned - Stock Titan

Feb 05, 2026

Jan 28, 2026

Propanc Biopharma files fourth patent application in two months By Investing.com - Investing.com Australia

Jan 28, 2026

Jan 27, 2026

Propanc Biopharma files fourth patent application in two months - Investing.com

Jan 27, 2026

Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations - marketscreener.com

Jan 27, 2026

Propanc Biopharma Accelerates IP Momentum: Files Fourth - GlobeNewswire

Jan 27, 2026

Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two MonthsStrengthening Global Protection for Breakthrough Proenzyme Formulations - The Manila Times

Jan 27, 2026

Jan 20, 2026

Propanc Biopharma files new patent for synthetic cancer treatment - Investing.com

Jan 20, 2026

Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia - The Manila Times

Jan 20, 2026

Propanc Biopharma, Inc. Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia - marketscreener.com

Jan 20, 2026

Propanc Biopharma files new patent for synthetic cancer treatment By Investing.com - Investing.com Nigeria

Jan 20, 2026

Jan 16, 2026

Propanc Biopharma advances pancreatic cancer treatment toward clinical trials By Investing.com - Investing.com Nigeria

Jan 16, 2026

Jan 15, 2026

Propanc Biopharma advances pancreatic cancer treatment toward clinical trials - Investing.com

Jan 15, 2026

Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer - The Manila Times

Jan 15, 2026

Two pancreatic proenzymes could offer new options for deadly cancer - Stock Titan

Jan 15, 2026

Jan 14, 2026

Propanc Biopharma plans phase 1b trial for cancer treatment PRP By Investing.com - Investing.com Canada

Jan 14, 2026

Jan 13, 2026

Propanc Biopharma plans phase 1b trial for cancer treatment PRP - Investing.com

Jan 13, 2026

Propanc Biopharma Provides Shareholder Update - The Manila Times

Jan 13, 2026

Cancer-focused biopharma Propanc plans 2026 human trial, fibrosis work - Stock Titan

Jan 13, 2026

Jan 09, 2026

Contrasting GRAIL (NASDAQ:GRAL) and Propanc Biopharma (OTCMKTS:PPCB) - Defense World

Jan 09, 2026

Jan 07, 2026

Propanc Biopharma Receives Nasdaq Minimum Bid Price Notice - TipRanks

Jan 07, 2026

Propanc Biopharma Received Notice of Noncompliance - TradingView — Track All Markets

Jan 07, 2026

Dec 30, 2025

Propanc Biopharma (NASDAQ: PPCB) details 2M-share Series C resale - Stock Titan

Dec 30, 2025

Propanc Biopharma files prospectus for resale of 2 million shares by selling stockholderSEC filing - marketscreener.com

Dec 30, 2025

Dec 22, 2025

When Wall Street Rotates, Biotech Innovators Emerge: The Untapped Opportunities in Oncology - The Globe and Mail

Dec 22, 2025

Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal - The Manila Times

Dec 22, 2025

Study tests enzyme mix that may disrupt deadly pancreatic tumors' support cells - Stock Titan

Dec 22, 2025

Dec 14, 2025